Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lanthanum Carbonate Granule · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule | DRUG | BAY77-1931 Granule TID for 4 days |
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet | DRUG | BAY77-1931 Chewable tablet TID for 4 days |
Inclusion Criteria: * Japanese male volunteers who must have given their written informed consent to participate in the study * Age is between 20 and 45 years * Body Mass Index (BMI) is between 17.6 and 26.4 kg/m2. * Volunteers who are judged by the investigators to be suitable for enrollment in th...
Lanthanum carbonate granule is being developed for hyperphosphatemia, a condition of elevated phosphate levels in the blood. The granule formulation is studied in a Phase 1 bioequivalence trial in Japan. It is an investigational formulation and is not described as approved in this program.
Lanthanum carbonate granule is being developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor associated with the clinical program for this granule formulation of lanthanum carbonate in hyperphosphatemia.
Lanthanum carbonate granule is in Phase 1 development. The program includes one completed Phase 1 trial with 59 enrolled participants. No active trials are listed, and the drug is investigational rather than approved for the hyperphosphatemia indication.
Lanthanum carbonate granule has been studied in NCT01053676, titled Bioequivalence Study of BAY77-1931 Granule. This completed Phase 1 trial enrolled 59 participants in Japan, used an active-controlled, randomized design, and included healthy male volunteers aged 20 years and older.
Lanthanum carbonate granule is also known as lanthanum carbonate (Fosrenol, BAY77-1931) granule. Fosrenol and BAY77-1931 are alternative names associated with lanthanum carbonate, and the granule refers to this specific oral formulation studied under the BAY77-1931 granule designation.